© 1999 American Heart Association, Inc.
Original Contributions |
Effect of Cardiopulmonary Bypass and Heparin on Plasma Levels of Lp(a) and Apo(a) Fragments
From the Departments of Internal Medicine (V.M., P.F., V.L., P.N.) and Cardiovascular Surgery (F.T., P.R., L.K.v.S.), the Central Laboratory of Clinical Chemistry (M.V., M.M.), and Medical Policlinic (R.D.), CHUV University Hospital, Lausanne, Switzerland; and the Department of Medicine, Northwest Lipid Research Laboratories, University of Washington, Seattle (S.M.M.).
Correspondence to Vincent Mooser, MD, Department of Internal Medicine, BH 19/135, CH-1011 CHUV Lausanne, Switzerland. E-mail vincent.mooser{at}hola.hospvd.ch
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Abstract—Fragments of apolipoprotein(a) [apo(a)], the distinctive glycoprotein of lipoprotein(a) [Lp(a)], are present in human plasma and urine and have been implicated in the development of atherosclerosis. The mechanism responsible for the generation of apo(a) fragments in vivo is poorly understood. In this study, we examined the plasma levels of Lp(a) and apo(a) fragments [or free apo(a)] and urinary apo(a) in 15 subjects who underwent cardiac surgery necessitating cardiopulmonary bypass. We also measured the plasma concentration and activity of polymorphonuclear elastase, an Lp(a)-cleaving enzyme in vitro, and plasma levels of C-reactive protein. Despite a marked activation of polymorphonuclear cells and a pronounced inflammatory response, as documented by an 8-fold and a 35-fold increase in plasma levels of polymorphonuclear elastase and C-reactive protein, respectively, the proportion of plasma free apo(a) to Lp(a) and urinary excretion of apo(a) remained unchanged over a 7-day period after surgery, and polymorphonuclear elastase activity remained undetectable in plasma. No fragmentation of apo(a) was observed ex vivo in plasma samples collected before and after surgery. These data indicate that in this model, apo(a) is not fragmented in plasma and are consistent with the hypothesis that apo(a) fragments result from a constitutively active tissue mechanism that is not modified by cardiac surgery with cardiopulmonary bypass.
Key Words: apolipoprotein(a) • atherosclerosis • elastase • heparin • lipoprotein(a)
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Apolipoprotein(a) [apo(a)] is a glycoprotein of unknown function1 that is associated with the premature development of atherosclerosis.2 3 4 Full-length apo(a) and fragments of apo(a) have been identified in human plasma.5 More than 99% of full-length apo(a) is attached to apolipoprotein B-100 (apoB) of LDL and circulates as part of lipoprotein(a) [Lp(a)]. Plasma Lp(a) levels vary widely between individuals and are largely determined by sequences at or close to the apo(a) locus.6 7 8 The apo(a) gene is homologous to the plasminogen gene.9 Plasminogen contains 5 kringles (K) and the protease domain. In contrast, the apo(a) gene is highly polymorphic due to a variable number of tandemly repeated copies of a motif resembling kringle 4 (K4) of plasminogen. In apo(a), the array of apo(a)-K4 repeats is followed by 1 K5 unit and the protease domain, which is functionally inactive. K4-containing fragments from the N-terminus of apo(a) are present in human plasma and urine.10 11 12 In plasma, the percentage of apo(a) fragments to Lp(a) is correlated inversely with plasma Lp(a) levels.5 13
The mechanism by which apo(a)/Lp(a) is atherogenic is not known. Identification of apo(a) fragments in atherosclerotic plaques14 has raised the hypothesis that fragments of apo(a) may contribute to the atherogenicity of Lp(a). As a consequence, interest has been generated regarding the molecular mechanism responsible for the production of apo(a) fragments.15 Apo(a) fragments do not appear to be secreted by hepatocytes but are more likely products of extracellular cleavage of apo(a)/Lp(a).5 However, the enzyme(s) responsible for this reaction and the site in which it takes place are not known. Recent in vitro studies by Scanu's group have identified polymorphonuclear (PMN) elastase as an apo(a)/Lp(a)-cleaving enzyme.16 17 Indeed, cleavage of apo(a)/Lp(a) by PMN elastase at various interkringle sites generates N-terminus fragments of apo(a) similar in size to those identified in human plasma and "mini-Lp(a)."18 Mini-Lp(a), which contains the C-terminus of the tandem array of K4 repeats, K5, and the protease domain of apo(a) attached to apoB, is not detected in plasma,5 suggesting that mini-Lp(a), which has maintained its ability to bind fibrin18 and heparin, is retained within the extracellular matrix,19 whereas N-terminus fragments of apo(a) are released into the circulation. Whether this scenario is operative in vivo is not known. Elucidation of the mechanism responsible for the generation of apo(a) fragments in vivo is hampered by the unusual species distribution of apo(a), which is restricted to humans, Old World monkeys, and hedgehogs. Finally, apo(a) fragments are not present in plasma from transgenic mice expressing human apo(a).5
To better understand the mechanism responsible for the generation of apo(a) fragments in vivo in humans, we measured serially the plasma levels of Lp(a) and apo(a) fragments [or free apo(a)] and urinary apo(a) in 15 subjects who underwent elective cardiac surgery with cardiopulmonary bypass (CPB). This type of surgery was chosen as a "model" because this well-standardized and well-documented procedure is accompanied by a major, acute, and transient inflammatory response that includes activation of PMN cells and the release into the circulation of large amounts of PMN elastase.20 PMN elastase has been implicated in acute lung injury and microvascular permeability after CPB.21 22 Next, the effect of surgery with CPB on plasma Lp(a) levels remains an unresolved issue, with some investigators reporting increased23 or unchanged24 25 plasma Lp(a) levels after this procedure. Finally, we took advantage of this model to examine whether a large bolus of heparin has the ability to release tissue-bound Lp(a) into the circulation. As for CPB, the effect of heparin on plasma Lp(a) levels has previously been examined, but conflicting results have been reported.19 26 27
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Subjects and Study Design
Participants to this study were recruited from those patients who underwent elective cardiac surgery necessitating CPB. Individuals with plasma creatinine levels >110 µmol/L; those who had suffered an acute illness or myocardial infarction or had undergone major surgery within 4 weeks preceding CPB; and those who presented with major abnormalities in lipid metabolism were excluded from the study. After median sternotomy, a bolus of heparin was injected (300 IU/kg body weight), and the CPB circuit was installed. CPB was performed with disposable membrane oxygenators and was primed with Ringer's lactate buffer, 5000 IU/L of heparin, and 106 IU aprotinin. Subjects were followed up for a 1-week period after surgery.
A total of 5 mL of blood was collected at 9 different time points from the intravenous line after it had been flushed. Blood was collected 1 hour before surgery (T1); immediately before heparin administration (T2);15 minutes after heparin administration (T3); 60 minutes after initiation of CPB (T4); at completion of surgery (T5); and at 4, 24, and 48 hours and 7 days after surgery (T6 through T9, respectively). Urine samples were collected at times T2 and at T5 through T9. Blood was collected in EDTA-containing tubes and maintained on ice for a maximum of 2 hours before centrifugation. An exception was T6, for which blood samples were stored for 12 hours at 4°C before centrifugation. Plasma was isolated and aliquots were stored at -80°C. All assays were performed on freshly thawed plasma samples except for cholesterol and triglyceride levels, which were assayed in plasma samples that had been thawed and refrozen once. Additional plasma and serum samples were collected from 4 severely ill subjects who had been admitted to the surgical intensive care unit of the hospital. The protocol was approved by the local ethics committee, and all participants gave their informed consent.
Laboratory Methods
Plasma levels of Lp(a) were quantified by an
ELISA.28 This assay uses IgG-a6 as a capture mouse
monoclonal antibody (Mab) and IgG-a40 as a detecting Mab. IgG-a6 and
IgG-a40 recognize epitopes in the N-terminus and the
C-terminus of apo(a), respectively. Plasma free apo(a) was
separated from Lp(a) by the heparin-Sepharose
chromatography method, as described.5
Free apo(a) was assayed in the nonretained fraction by ELISA with
IgG-a6 as the capture antibody and IgG-a5, an Mab directed against the
N-terminus of apo(a), as the detecting antibody. In
addition, apo(a) in untreated plasma and in the heparin-unbound
fraction was examined by immunoblot analysis by 5%
SDS–polyacrylamide gel electrophoresis, as
described.29 The size of the apo(a) isoforms in
plasma was determined as described.30 Apo(a) in urine was
quantified using the same ELISA as for free apo(a).11
Plasma levels of PMN elastase were measured using a homogeneous immunoturbidimetric assay (PMN elastase, Ecoline Merck) on a Cobas Mira Plus analyzer (Roche) according to the manufacturer's instructions. The interassay CV was <4% for values <130 µg/L. Normal values for this assay were 29 to 86 µg/L, with a detection level of 9 µg/L. Measurement of the activity of PMN elastase in plasma was performed using a colorimetric assay.31 This assay uses 3-carboxypropionyl-Ala-Ala-Val-4-nitroaniline as a specific substrate for PMN elastase and detects generation of the yellow product 4-nitroaniline. Control for the assay was performed by comparing the concentration of PMN elastase and the elastolytic activity in the supernatant after stimulation of purified PMN cells with fMet-Leu-Phe (1 µmol/L) and cytochalasin B (5 µg/mL). In this assay, the activity of 200 µg of PMN elastase corresponded to the digestion of 1 µmol/min of specific substrate.
Plasma levels of creatine kinase (CK), creatinine, and albumin were assayed according to the manufacturer's instructions on a Hitachi 717 selective analyzer (Boehringer Mannheim). Creatinine in urine was measured similarly on a Hitachi 704 analyzer. C-reactive protein (CRP) was assayed using a homogeneous immunoturbidimetric assay (Dako) on a Hitachi 717 analyzer. The interassay CV was 3% for values between 30 and 100 mg/L. Reference values for plasma CRP levels were <10 mg/L. Plasma concentrations of cholesterol and triglycerides were determined using the Unimate5-CHOL and Unimate7-TRIG kits, respectively (Roche). HDL cholesterol levels were measured using the same kit after precipitation of apoB-containing lipoproteins by the phosphotungstate-MgCl2 method (Boehringer-Mannheim). The LDL cholesterol fraction was calculated using the Friedewald formula.
Data are expressed as mean±SEM, or median where indicated. Statistical analysis was performed using the STATA package (Stata Corp, College Station, Tex). One-way ANOVA was used to test for variance during the study period. In case of variance, the analysis was completed by paired t tests [or Wilcoxon rank-sum test in the case of plasma Lp(a) levels] to detect significant changes from baseline.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
A total of 9 males and 6 females aged 45 to 72 years participated in the study. Two subjects were on lipid-lowering therapy, whereas 4 individuals were diabetics. Ten subjects underwent CPB for coronary artery bypass grafting (CABG), 4 for valve replacement, and 1 for both valve replacement and CABG on 1 vessel. None of the subjects had any acute condition, renal insufficiency, or major lipid abnormalities. No major complication was observed in the perioperative or postoperative period. Baseline plasma Lp(a) levels ranged from 0.3 to 79.4 mg/dL (median, 11.1 mg/dL). The size of the apo(a) isoforms ranged from 20 to 36 K4 repeats, and an inverse relationship was apparent between plasma Lp(a) levels and the size of the apo(a) isoforms in plasma.
Initiation of CPB was associated with an abrupt reduction in hematocrit
[from 0.43±0.02 at baseline to 0.33±0.01 (mean±SEM) 4 hours after
completion of surgery]; (Table
).
Changes in hematocrit were paralleled by reductions in plasma
levels of albumin and total, HDL, and LDL
cholesterol (from 3.0±0.2 mmol/L to 1.8±0.2
mmol/L). These acute changes were mainly due to hemodilution induced by
the large volume of Ringer's lactate buffer used to prime the CPB
circuit. Cardiac surgery with CPB was associated with a 35-fold
increase in plasma CRP levels (from 6±2 mg/L at baseline to 209±23
mg/L 48 hours after surgery, P<0.01) that tended to
normalize 1 week after surgery (48±5 mg/L). Changes in CRP levels were
paralleled by changes in CK levels (from 72±11 to 390±124 mg/L,
P<0.01) and leukocyte counts (from 7.7±0.7 to
13.2±0.8x109/L, P<0.01). In
addition, plasma levels of immunoreactive PMN elastase rose from
37±4 to 269±27 µg/L (P<0.01) at completion of the
surgical procedure and decreased progressively in the postsurgical
period to 66±11 mg/L after 1 week. These observations reflect the
importance of the acute and transient inflammatory response generated
by surgery with CPB.
|
The individual profiles of plasma Lp(a) levels during the study period
are illustrated in Figure 1 (upper
panel). Plasma Lp(a) levels were unaffected by administration of a
large bolus of heparin [11.4 before versus 10.9 mg/dL after heparin
(median)]. Installation of the CPB circuit and priming of the machine
induced a sharp reduction in plasma levels of Lp(a). During surgery,
plasma levels of Lp(a) evolved in parallel with those of total, HDL,
and LDL cholesterol, as illustrated by the ratio of plasma
Lp(a) to LDL cholesterol levels that remained unchanged
from time T1 to T6 (the Table
). However, plasma levels of Lp(a)
returned to baseline at time T9, whereas plasma levels of total and LDL
cholesterol were significantly below baseline values at
completion of the study.
|
Plasma levels of free apo(a) and the percentage of free apo(a) to Lp(a)
rose acutely during CPB (the Table). This phenomenon was due to
incomplete removal of Lp(a) when using heparin-Sepharose
chromatography in the presence of heparin in plasma, as
assessed by immunoblot analysis of apo(a) in
untreated plasma and in the heparin-unbound fraction (Figure 2). In the postsurgical period, plasma
levels of free apo(a) closely paralleled plasma Lp(a) levels
(Figure 1, second panel), with the lowest concentrations at 48
hours after surgery (0.35±0.06 versus 0.70±0.12 mg/dL at baseline,
P<0.05). Apart from the values obtained during CPB, the
pattern of apo(a) fragments (Figure 2) and the ratio of free
apo(a) to Lp(a) remained remarkably stable throughout the study period
(2.8±0.4% at baseline, 3.0±0.5% 4 hours after surgery, and
3.1±0.5% at 48 hours after surgery, the Table), with a slight
reduction to 2.0±0.3% by day 7 (P=NS).
|
It is conceivable that an acceleration in apo(a) fragmentation went
unnoticed due to the rapid and efficient excretion of apo(a) fragments
into the urine. To address this question, urine was collected at
baseline (T2) and in the postsurgical period (T5 to T9), and urinary
apo(a) was quantified. The concentration of urinary apo(a) decreased
from 0.17±0.05 µg/mL at baseline to 0.08±0.02 µg/mL at completion
of the surgery and increased progressively in the postsurgical period
(Figure 1, third panel). Urinary levels of apo(a) and
creatinine (open triangles) evolved in parallel, indicating
that the changes in urinary apo(a) levels were mainly due to variations
in urinary output. To circumvent the problem of variable
diuresis, we normalized the concentration of urinary apo(a)
with respect to urine creatinine levels. At baseline,
urinary excretion of apo(a) averaged 29.7±4.9 µg/mmol of
creatinine and remained relatively stable throughout the
study period (Figure 1, lower panel). Taken together, these
observations indicated that even if fragmentation of apo(a) had been
accelerated by CPB, the apo(a) fragments that were generated did not
accumulate in the plasma or urine.
To gain further insight into the generation of apo(a) fragments, we performed ex vivo experiments on plasma samples collected before and after surgery from 4 subjects with baseline plasma Lp(a) levels ranging from 6.4 to 25.7 mg/dL. Plasma samples were incubated at 37°C for 1 or 4 hours, and plasma levels of Lp(a) and free apo(a) were quantified. In plasma samples collected before surgery, the proportion of free apo(a) to Lp(a) averaged 1.7±0.4% before incubation, 2.1±0.8% after a 1-hour, and 1.7±0.3% after a 4-hr incubation at 37°C. The respective values for plasma samples collected after CPB (T5) were 1.6±0.2%, 1.4±0.3%, and 1.4±0.4%. These data indicate that fragmentation of apo(a) is unlikely to happen in plasma, even after a major insult like CPB. The absence of apo(a) fragmentation in plasma prompted us to examine the activity of PMN elastase in plasma. No PMN elastase activity was detected in plasma samples collected at times T1, T5, T6, and T9, indicating that in this situation, PMN-derived elastase in plasma is biologically inactive.
Next, we examined whether a major insult other than CPB would be accompanied by apo(a) fragmentation in plasma. Plasma and serum samples were collected from 4 severely ill subjects admitted to the surgical intensive care unit of the hospital. One subject had acute respiratory distress syndrome, the second had polytrauma, and the remaining 2 subjects had extensive burns (>25% of body surface area). Plasma levels of Lp(a) ranged from 5.0 to 25 mg/dL, CRP from 164 to 424 mg/L, and leukocyte counts from 109/L to 17.4x109/L. Individual plasma elastase concentrations were 542, 363, 131, and 179 µg/L; however, no significant PMN elastase activity was detected in these plasma samples. No generation of apo(a) fragments was observed in plasma samples after 1 (3.0±0.5% versus 3.0±0.4% before incubation) and 4 (3.3±0.4%) hours of incubation at 37°C, indicating that, as is the case for CPB, fragmentation of apo(a) in plasma is unlikely to occur in these situations.
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The presence in healthy volunteers of apo(a) fragments in plasma and urine, coupled with the observation that apo(a) fragments are not produced by hepatocytes in monkeys,5 indicates the existence of an extracellular mechanism responsible for the cleavage of Lp(a)/apo(a). The present study was designed to evaluate whether this cleavage mechanism is accelerated when humans are exposed to a major insult and whether this mechanism is operative in plasma. Our data show that the proportion of plasma free apo(a) to Lp(a) and the urinary excretion of apo(a) remained unchanged after surgery with CPB, despite a marked inflammatory response. In addition, no increase in plasma PMN elastase activity was noticed during CPB, and no fragmentation of apo(a) in plasma was observed ex vivo.
To our knowledge, this is the first study to perform serial
measurements of plasma levels of free apo(a) and urinary apo(a) in
humans. The stability of the proportions of plasma levels of free
apo(a) to Lp(a) was unexpected, given the marked inflammatory response
generated by CPB. Several mechanisms can be proposed to account for
this observation. It is conceivable that apo(a) fragmentation was
accelerated in tissues after CPB but that this phenomenon remained
unnoticed owing to the retention of apo(a) fragments within the
extravascular compartment or to a rapid clearance of these fragments.
This latter hypothesis, however, is unlikely, because no accumulation
of apo(a) fragments was observed in urine. More likely, our data
indicate that the tissue mechanism responsible for the generation of
apo(a) fragments is unaffected by CPB and that fragmentation of apo(a)
does not occur in plasma. The absence of apo(a) fragmentation in
plasma, despite the large amount of PMN elastase released after
CPB, is probably due to the presence of excess protease
inhibitors like 
1-antitrypsin.
However, we cannot formally rule out the possibility that aprotinin,
which was present in the CPB priming buffer, may have inhibited the
fragmentation of apo(a), even when administered at minimal doses, as
was the case here.32 Such a hypothesis, however, is
unlikely. First, no reduction in the plasma free apo(a) to Lp(a) ratio
was observed during CPB, indicating that cleavage of apo(a)/Lp(a) is
not aprotinin-sensitive. Next, no apo(a) fragmentation was observed in
plasma from 4 severely ill subjects who had not received any protease
inhibitors.
Our data also show that Lp(a), when attached to tissues, cannot be displaced by a large bolus of heparin. This finding is in agreement with those of other investigators19 who had reported no change in plasma Lp(a) levels after administration of smaller doses of heparin to volunteers. The reason why our data differ from those of other investigators who have observed an increase33 or a decrease27 in plasma Lp(a) levels after heparin administration is not known and may be related to the different types of patients or heparin administration.
Plasma levels of Lp(a) and LDL cholesterol evolved in
parallel during the surgical procedure. However, in the postsurgical
period, plasma Lp(a) levels returned to values above baseline at day 7,
at a time when plasma LDL cholesterol levels were still
30% below baseline. The evolution of plasma Lp(a) levels as
observed here was similar to the one previously reported after
CPB,25 other surgical interventions,34 after
myocardial infarction,34 35 36 or after administration of
bisphosphonates.37 Taken together, these observations are
consistent with the concept that Lp(a) reacts to inflammation,
even when the Lp(a) response is delayed compared with the typical
acute-phase reactant CRP.34 38
At the present time, whether apo(a) fragments have a biological function in plasma or in urine and whether they participate in the development of atherosclerosis remain to be established. If the role of apo(a) fragments in the development of atherosclerosis is once confirmed, identification of the mechanism responsible for their generation or their excretion may potentially unravel novel targets in the prevention and the treatment of this disease.
|
Acknowledgments |
|---|
This study was supported by the Swiss Foundation for Scientific Research (SCORE grant 32-44471.95 to V.M.), the Fondation Placide Nicod, and a grant (HL30086 to S.M.M.) from the National Institutes of Health, Bethesda, Md. The authors wish to thank Pierre-Guy Chassot, René Chioléro, and the nursing staff of the operating room and the surgical intensive care unit for their help in collecting blood and urine samples. The careful and critical reading of the manuscript by Helen Hobbs and Gérard Waeber was greatly appreciated.
Received June 2, 1998; accepted October 7, 1998.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Utermann G. The mysteries of lipoprotein(a). Science. 1989;246:904–910.
2.
Dahlen GH, Guyton JR, Attar M, Farmer JA, Kautz JA,
Gotto AMJ. Association of levels of lipoprotein Lp(a), plasma lipids,
and other lipoproteins with coronary artery disease documented
by angiography. Circulation. 1986;74:758–765.
3.
Scanu AM. Lipoprotein(a): a genetic risk factor for
premature coronary heart disease. JAMA. 1992;267:3326–3329.
4.
Bostom AG, Cupples LA, Jenner JL, Ordovas JM, Semal
LJ, Wilson PWF, Schaefer EJ, Castelli WP. Elevated plasma
lipoprotein(a) and coronary heart disease in men aged 55 years
and younger: a prospective study. JAMA. 1996;276:544–548.
5. Mooser V, Marcovina SM, White AL, Hobbs HH. Kringle-containing fragments of apolipoprotein(a) circulate in human plasma and are excreted into the urine. J Clin Invest. 1996;98:2414–2424.[Medline] [Order article via Infotrieve]
6. Utermann G, Menzel HJ, Kraft HG, Duba HC, Kemmler HG, Seitz C. Lp(a) glycoprotein phenotypes: inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest. 1987;80:458–465.
7. Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest. 1992;90:52–60.
8. Mooser V, Sheer D, Marcovina SM, Wang J, Guerra R, Cohen J, Hobbs HH. The apo(a) gene is the major determinant of variation in plasma Lp(a) levels in African-Americans. Am J Hum Genet. 1997;61:402–417.[Medline] [Order article via Infotrieve]
9. McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM, Scanu AM, Lawn RM. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 1987;330:132–137.[Medline] [Order article via Infotrieve]
10.
Oida K, Takai H, Maeda H, Takahashi S, Shimada A,
Suzuki J, Tamai T, Nakai T, Miyabo S. Apolipoprotein(a) is present
in urine and its excretion is decreased in patients with renal failure.
Clin Chem. 1992;38:2244–2248.
11. Mooser V, Seabra MC, Abedin M, Landschulz KT, Marcovina SM, Hobbs HH. Apo(a) kringle-4 containing fragments in human urine: relationship to plasma levels of lipoprotein(a). J Clin Invest. 1996;97:858–864.[Medline] [Order article via Infotrieve]
12.
Kostner KM, Maurer G, Huber K, Stefenelli T, Dieplinger
H, Steyrer E, Kostner GM. Urinary excretion of apo(a) fragments: role
in apo(a) catabolism. Arterioscler Thromb Vasc Biol. 1996;16:905–911.
13. Trenkwalder E, Gruber A, Konig P, Dieplinger H, Kronenberg F. Increased plasma concentrations of LDL-unbound apo(a) in patients with end-stage renal disease. Kidney Int. 1997;52:1685–1692.[Medline] [Order article via Infotrieve]
14. Hoff HF, O'Neil J, Smejkal GB, Yashiro A. Immunochemically detectable lipid-free apo(a) in plasma and in human atherosclerotic lesions. Chem Phys Lipids. 1994;67:271–280.
15. Scanu AM, Edelstein C. Learning about the structure and biology of human lipoprotein(a) through dissection by enzymes of the elastase family: facts and speculations. J Lipid Res. 1997;38:2193–2206.[Abstract]
16. Edelstein C, Italia JI, Klezovitch O, Scanu AM. Functional and metabolic differences between elastase-generated fragments of human lipoprotein(a) and apolipoprotein(a). J Lipid Res. 1996;37:1786–1801.[Abstract]
17.
Edelstein C, Italia JI, Scanu AM. Polymorphonuclear
cells isolated from human peripheral blood cleave Lp(a) and
apo(a) at multiple interkringle sites via the enzyme elastase:
generation of mini-Lp(a) particles and apo(a) fragments. J
Biol Chem. 1997;272:11079–11087.
18. Huby T, Schroeder W, Doucet C, Chapman J, Thillet J. Characterization of the N-terminal and C-terminal domains of human apolipoprotein(a): relevance to fibrin binding. Biochemistry. 1995;34:7385–7393.[Medline] [Order article via Infotrieve]
19. Van Barlingen HHJJ, Kleinveld HA, Erkelens DW, de Bruin TWA. Lipoprotein lipase-enhanced binding of lipoprotein(a) [Lp(a)] to heparan sulfate is improved by apolipoprotein E (apoE) saturation: secretion-capture process of apoE is a possible route for the catabolism of Lp(a). Metabolism. 1997;46:650–655.[Medline] [Order article via Infotrieve]
20. Riegel W, Spillner G, Schlosser V. Plasma levels of main granulocyte components during cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1988;95:1014–1019.[Abstract]
21.
Tönz M, Mihaljevic T, Von Segesser K, Fehr J,
Schmid ER, Turina MI. Acute lung injury during cardiopulmonary
bypass: are the neutrophils responsible? Chest. 1995;108:1551–1556.
22.
Larson DF, Bowers M, Schechner HW. Neutrophil
activation during cardiopulmonary bypass in paediatric and
adult patients. Perfusion. 1996;11:21–27.
23. Sgoutas DS, Lattouf OM, Finlayson DC, Clark RV. Paradoxical response of plasma lipoprotein(a) in patients undergoing cardiopulmonary bypass. Atherosclerosis. 1992;97:29–36.[Medline] [Order article via Infotrieve]
24. Moliterno DJ, Jessen ME, Schueler K, Cohen J. Plasma lipoprotein(a) concentrations are not elevated by cardiopulmonary bypass. Atherosclerosis. 1993;104:223–225.[Medline] [Order article via Infotrieve]
25. Cobbaert C, Louisa A, Struijk L, Demeyere R, Meyns B. Lipoprotein(a) changes during and after coronary artery bypass grafting: an epiphenomenon ? Ann Clin Biochem. 1998;35:75–79.
26. Sagripanti A, Cozza V, Barsotti G. Low-molecular-weight heparin and lipoprotein(a) in patients with chronic renal failure. Nephron. 1997;76:123–124.[Medline] [Order article via Infotrieve]
27. Salvini P, Maddaloni E, Levi della Vida MV, Parma A, Corpetti MG, Di Lorenzo M. Heparin and lipoprotein(a): observations during hemodialysis. Recenti Prog Med. 1993;84:828–833.[Medline] [Order article via Infotrieve]
28. Marcovina SM, Albers JJ, Gabel B, Koschinsky ML, Gaur VP. Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). Clin Chem. 1995;41/2:246–255.
29. Lackner C, Cohen JC, Hobbs HH. Molecular basis of apolipoprotein(a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis. J Clin Invest. 1991;87:2077–2086.
30.
Lackner C, Boerwinkle E, Leffert CC, Rahmig T, Hobbs
HH. Molecular definition of the extreme size polymorphism in
apolipoprotein(a). Hum Mol Genet. 1993;2:933–940.
31. Fritz H. Enzymes 3: peptidases, proteinases and their inhibitors. In: Methods of Enzymatic Analysis. 3rd ed. Weinheim, Germany: Verlag Chemie; 1981;5:176–184.
32.
Hayashida N, Isomura T, Sato T, Maruyama H, Kosuga K,
Aoyagi S. Effects of minimal-dose aprotinin on coronary artery
bypass grafting. J Thorac Cardiovasc Surg. 1997;114:261–269.
33. Kronenberg F, Koenig P, Neyer U, Auinger M, Pribasnig A, Meisl T, Pinter G, Dieplinger H. Influence of various heparin preparations on lipoproteins in hemodialysis patients: a multicentre study. Thromb Haemost. 1995;74:1025–1028.[Medline] [Order article via Infotrieve]
34. Maeda S, Abe A, Seishima M, Makino K, Noma A, Kawade M. Transient changes of serum lipoprotein(a) as an acute phase protein. Atherosclerosis. 1989;78:145–150.[Medline] [Order article via Infotrieve]
35. Andreassen A, Berg K, Torsvik H. Changes in Lp(a) lipoprotein and other plasma proteins during acute myocardial infarction. Clin Genet. 1994;46:410–416.[Medline] [Order article via Infotrieve]
36. Husain M, Armstrong PW, Connelly PW, Hegele RA. Lipoprotein(a) and apolipoproteins B and A-1 after acute myocardial infarction. Can J Cardiol. 1995;11:206–210.[Medline] [Order article via Infotrieve]
37. Lippi G, Braga V, Adami S, Guidi G. Modification of serum apolipoprotein A-1, apolipoprotein B and lipoprotein(a) levels after bisphosphonates-induced acute phase response. Clin Chim Acta. 1998;271:79–87.[Medline] [Order article via Infotrieve]
38. Ledue TB, Neveux LM, Palomaki GE, Ritchie RF, Craig WY. The relationship between serum levels of lipoprotein(a) and proteins associated with the acute phase response. Clin Chim Acta. 1993;223:73–82.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  S. Gonbert, B. Saint-Jore, P. Giral, C. Doucet, J. Chapman, and J. Thillet Molecular Analysis of Apo(a) Fragmentation in Polygenic Hypercholesterolemia: Characterization of a New Plasma Fragment Pattern Arterioscler. Thromb. Vasc. Biol., August 1, 2001; 21(8): 1353 - 1358. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Mooser, M. M. Berger, L. Tappy, C. Cayeux, S. M. Marcovina, R. Darioli, P. Nicod, and R. Chiolero Major Reduction in Plasma Lp(a) Levels During Sepsis and Burns Arterioscler. Thromb. Vasc. Biol., April 1, 2000; 20(4): 1137 - 1142. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||